VANI Vivani Medical, Inc.

Nasdaq vivani.com


$ 1.44 $ 0.00 (0 %)    

Tuesday, 18-Nov-2025 07:50:35 EST
QQQ $ 599.37 $ 0.00 (0 %)
DIA $ 462.93 $ 0.00 (0 %)
SPY $ 661.82 $ 0.00 (0 %)
TLT $ 89.42 $ 0.00 (0 %)
GLD $ 371.05 $ 0.00 (0 %)
$ 1.47
$ 1.45
$ 1.42 x 500
$ 1.44 x 107
-- - --
$ 0.91 - $ 1.92
301,264
na
107.24M
$ 2.76
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-13-2025 09-30-2025 10-Q
2 08-13-2025 06-30-2025 10-Q
3 05-13-2025 03-31-2025 10-Q
4 03-31-2025 12-31-2024 10-K
5 11-13-2024 09-30-2024 10-Q
6 08-13-2024 06-30-2024 10-Q
7 05-13-2024 03-31-2024 10-Q
8 03-26-2024 12-31-2023 10-K
9 11-13-2023 09-30-2023 10-Q
10 08-14-2023 06-30-2023 10-Q
11 05-15-2023 03-31-2023 10-Q
12 03-31-2023 12-31-2022 10-K
13 11-14-2022 09-30-2022 10-Q
14 08-11-2022 06-30-2022 10-Q
15 05-16-2022 03-31-2022 10-Q
16 03-29-2022 12-31-2021 10-K
17 11-12-2021 09-30-2021 10-Q
18 08-13-2021 06-30-2021 10-Q
19 05-13-2021 03-31-2021 10-Q
20 03-16-2021 12-31-2020 10-K
21 11-12-2020 09-30-2020 10-Q
22 08-13-2020 06-30-2020 10-Q
23 06-26-2020 03-31-2020 10-Q
24 03-19-2020 12-31-2019 10-K
25 11-14-2019 09-30-2019 10-Q
26 08-06-2019 06-30-2019 10-Q
27 05-15-2019 03-31-2019 10-Q
28 03-19-2019 12-31-2018 10-K
29 11-08-2018 09-30-2018 10-Q
30 08-07-2018 06-30-2018 10-Q
31 05-15-2018 03-31-2018 10-Q
32 03-20-2018 12-31-2017 10-K
33 11-06-2017 09-30-2017 10-Q
34 08-07-2017 06-30-2017 10-Q
35 05-09-2017 03-31-2017 10-Q
36 03-16-2017 12-31-2016 10-K
37 11-04-2016 09-30-2016 10-Q
38 08-08-2016 06-30-2016 10-Q
39 05-06-2016 03-31-2016 10-Q
40 03-11-2016 12-31-2015 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 vivani-medical-q3-eps-011-inline

Vivani Medical (NASDAQ:VANI) reported quarterly losses of $(0.11) per share which met the analyst consensus estimate. This is u...

 vivani-medical-expects-to-spin-off-cortigent-unit-starts-clinical-development-of-npm-139-semaglutide-implant-in-obesity-chronic-weight-management-in-2026

Vivani Medical, Inc. (NASDAQ:VANI) ("Vivani" or the "Company"), a biopharmaceutical company developing miniatur...

 vivani-medical-announces-company-presentation-unveils-obesity-market-strategy-with-new-glp-1-implant-technology

https://d1io3yog0oux5.cloudfront.net/_8b0e72ba9731939ad4ef3d445345826e/vivanimedical/db/2227/20875/pdf/Vivani+Corporate+Present...

 vivani-sets-october-8-record-date-for-spin-off-of-cortigent-to-trade-under-nasdaq-ticker-crgt

Cortigent is a leading developer of brain implant devices based on precision neurostimulation technology. It is the only compan...

 vivani-medical-plans-to-initiate-phase-1-clinical-study-in-npm-139-semaglutide-implant-program-in-first-half-of-2026-pending-regulatory-clearance

NPM-139 has potential to provide Wegovy®-level efficacy with once or twice-yearly administrationFirst-in-human Phase 1 study is...

 hc-wainwright--co-reiterates-buy-on-vivani-medical-maintains-4-price-target

HC Wainwright & Co. analyst Yi Chen reiterates Vivani Medical (NASDAQ:VANI) with a Buy and maintains $4 price target.

 vivani-medical-q2-eps-012-misses-010-estimate

Vivani Medical (NASDAQ:VANI) reported quarterly losses of $(0.12) per share which missed the analyst consensus estimate of $(0....

 vivani-medical-announces-the-appointment-of-anthony-baldor-as-chief-financial-officer

Vivani Medical, Inc. (NASDAQ:VANI) ("Vivani" or the "Company"), a clinical-stage biopharmaceutical company deve...

 hc-wainwright--co-reiterates-buy-on-vivani-medical-maintains-4-price-target

HC Wainwright & Co. analyst Yi Chen reiterates Vivani Medical (NASDAQ:VANI) with a Buy and maintains $4 price target.

 vivani-medical-q1-eps-011-misses-010-estimate

Vivani Medical (NASDAQ:VANI) reported quarterly losses of $(0.11) per share which missed the analyst consensus estimate of $(0....

 hc-wainwright--co-reiterates-buy-on-vivani-medical-maintains-4-price-target

HC Wainwright & Co. analyst Yi Chen reiterates Vivani Medical (NASDAQ:VANI) with a Buy and maintains $4 price target.

 vivani-medical-expands-collaboration-with-okava-pharmaceuticals-to-include-dogs-in-development-of-okv-119-a-long-acting-glp-1-therapy-for-weight-management-diabetes-and-other-cardiometabolic-conditions

ALAMEDA, Calif. and SAN FRANCISCO, April 15, 2025 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ:VANI) ("Vivani" or t...

 hc-wainwright--co-reiterates-buy-on-vivani-medical-maintains-4-price-target

HC Wainwright & Co. analyst Yi Chen reiterates Vivani Medical (NASDAQ:VANI) with a Buy and maintains $4 price target.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION